Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery. Methods A retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Results Between January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91% and 82% at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI > 18 months. No cases of acute G3 toxicity or greater occurred. Conclusions SBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.

Original languageEnglish
Pages (from-to)735-742
Number of pages8
JournalEuropean Journal of Surgical Oncology
Volume43
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Radiosurgery
Pancreatic Neoplasms
Retrospective Studies
Recurrence
Disease-Free Survival
Survival
Therapeutics
Pancreatectomy
Terminology
Prescriptions
Survivors
Adenocarcinoma
Pain

Keywords

  • Pancreas cancer
  • RapidArc
  • SBRT
  • VMAT

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{0e4852d786554b5b8ea5aaba0fd72e3e,
title = "Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study",
abstract = "Objective To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery. Methods A retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Results Between January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91{\%} and 82{\%} at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI > 18 months. No cases of acute G3 toxicity or greater occurred. Conclusions SBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.",
keywords = "Pancreas cancer, RapidArc, SBRT, VMAT",
author = "T. Comito and L. Cozzi and A. Zerbi and C. Franzese and E. Clerici and A. Tozzi and C. Iftode and P. Navarria and G. D'Agostino and A. Fogliata and P. Mancosu and S. Tomatis and C. Carnaghi and N. Personeni and A. Santoro and M. Scorsetti",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.ejso.2016.12.012",
language = "English",
volume = "43",
pages = "735--742",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery

T2 - A retrospective study

AU - Comito, T.

AU - Cozzi, L.

AU - Zerbi, A.

AU - Franzese, C.

AU - Clerici, E.

AU - Tozzi, A.

AU - Iftode, C.

AU - Navarria, P.

AU - D'Agostino, G.

AU - Fogliata, A.

AU - Mancosu, P.

AU - Tomatis, S.

AU - Carnaghi, C.

AU - Personeni, N.

AU - Santoro, A.

AU - Scorsetti, M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery. Methods A retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Results Between January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91% and 82% at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI > 18 months. No cases of acute G3 toxicity or greater occurred. Conclusions SBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.

AB - Objective To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery. Methods A retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Results Between January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91% and 82% at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI > 18 months. No cases of acute G3 toxicity or greater occurred. Conclusions SBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.

KW - Pancreas cancer

KW - RapidArc

KW - SBRT

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=85010607989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010607989&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2016.12.012

DO - 10.1016/j.ejso.2016.12.012

M3 - Article

C2 - 28131670

AN - SCOPUS:85010607989

VL - 43

SP - 735

EP - 742

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 4

ER -